© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
June 19, 2022
The last decade of immunotherapy progress was based on decades of prior research, including other forms of immunotherapy.
March 28, 2022
Treatment options have expanded widely for patients with multiple myeloma
over the past several years, resulting in significantly improved outcomes for these patients.
August 16, 2021
The future is rapidly approaching; several hundred trials are using circulating tumor DNA detection and quantification for either intervention or observation.
July 19, 2021
In 2017, the American Society of Clinical Oncology and the Ontario Health-Cancer Care Ontario's non–small cell lung cancer expert panel published a guideline with recommendations for systemic therapy for patients with stage IV NSCLC.
April 18, 2021
Although curing advanced RCC is an admirable goal, there are many treatment options available on the horizon that result in substantial improvements in long-term outcomes.
March 30, 2021
Oncologists deciding what to do about coronavirus disease 2019 vaccines are not alone.